Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Multiple Myeloma Drugs Industry?

The market size for multiple myeloma drugs has seen substantial growth in recent times. It is projected to increase from $21.84 billion in 2024 to $23.03 billion in 2025, with a compound annual growth rate (CAGR) of 5.4%. Numerous factors have contributed to this growth in the past, including enhanced diagnostic techniques, successful clinical trials, better understanding of the disease, advancements in healthcare infrastructure, patient activism, and increased awareness.

The market size for multiple myeloma drugs is slated to witness robust expansion in the upcoming years, swelling to “$29.44 billion in 2029 with a compound annual growth rate (CAGR) of 6.3%.” Contributing factors to this projected growth during the forecast period encompass advancements in immunotherapy, the proliferation of targeted therapies, the utilisation of liquid biopsy, the rise of car-t cell therapy, and the breakthroughs in biomarker identification. Key trends during this period are expected to revolve around the emphasis on long-term survivorship, the investigation into epigenetic treatments, the increased use of telemedicine, broader availability of innovative therapies, and maintenance of myeloma care sustainability.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11943&type=smp

#Which Factors Are Currently Driving The Growth Of The Multiple Myeloma Drugs Market?

The expanding incidence of blood-related cancers is predicted to boost the multiple myeloma drugs market’s growth. These types of cancers originate in blood-forming tissues, such as bone marrow, or in white blood cells. This includes diseases like leukemia, lymphoma, multiple myeloma and others. Multiple myeloma drugs are commonly used to manage multiple myeloma by eliminating and controlling the expansion of cancer cells, reducing the rate of cell division, stimulating various enzymatic functions, and helping maintain bone strength and alleviating pain from weakened bones. For instance, the American Cancer Society (ACS) reported in January 2023 that there were roughly 59,610 newly diagnosed leukemia cases and approximately 20,380 cases of acute myeloid leukemia (AML). Furthermore, the total deaths attributed to leukemia were around 23,710. Thus, the rising occurrence of hematological cancer is propelling the growth of the multiple myeloma drugs market.

The multiple myeloma drugs market covered in this report is segmented –

1) By Drug Type: Immunomodulatory Drugs, Proteasome Inhibitors, Histone Deacetylase Inhibitors, Monoclonal Antibody Drugs, Steroids, Other Drug Types

2) By Therapy: Targeted Therapy, Biologic Therapy, Chemotherapy, Other Therapies

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels

4) By End-User: Men, Women

Subsegments:

1) By Immunomodulatory Drugs: Lenalidomide, Thalidomide, Pomalidomide

2) By Proteasome Inhibitors: Bortezomib, Carfilzomib, Ixazomib

3) By Histone Deacetylase Inhibitors: Panobinostat, Romidepsin

4) By Monoclonal Antibody Drugs: Daratumumab, Elotuzumab, Isatuximab

5) By Steroids: Dexamethasone, Prednisone

6) By Other Drug Types: Alkylating Agents, Antimetabolites, New Experimental Drugs

What Are The Leading Trends And Opportunities In The Multiple Myeloma Drugs Sector?

In the multiple myeloma drugs market, product innovation is becoming increasingly popular as a key trend. To solidify their market standing and carve out a competitive edge, top players in this market are placing great emphasis on the development of innovative products. In a notable move in March 2022, Janssen Biotech Inc., a biotech firm based in Japan, won approval from the United States Food and Drug Administration for Carvykti, its CAR T-Cell therapy (a form of personalized immunotherapy) targeting multiple myeloma. CARVYKTI, or ciltacabtagene autoleucel, is an autologous cell-based product that has undergone genetic modification. It utilizes T cells that have been transduced ex vivo with a replication-incompetent lentiviral vector responsible for encoding an anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CAR), comprised of two single domain antibodies tied to a 4-1BB costimulatory domain and a CD3-zeta signaling domain. Only patients who have undergone four or more therapy lines, comprising treatment with three crucial types of multiple myeloma drugs (an immunomodulating agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody), are considered qualified recipients for its use in the treatment of relapsed conditions.

Who Are The Main Participants Shaping The Multiple Myeloma Drugs Market Landscape?

Major companies operating in the multiple myeloma drugs market include Pfizer Inc., Johnson & Johnson Pvt. Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG., Roche Holding AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Kite Pharma Inc, Amgen Inc., AstraZeneca plc, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company, Daiichi Sankyo Co. Ltd., Lonza Group AG, Cipla Ltd., ONO Pharmaceutical Co. Ltd., BieGene Ltd., Biotest AG, Onyx Pharmaceuticals Inc., PharmaMar SA, Karyopharm Therapeutics Inc., Poseida Therapeutics Inc., ImmunoGen Inc., Oncopetides AB

https://www.thebusinessresearchcompany.com/report/multiple-myeloma-drugs-global-market-report

Which Region Currently Holds The Largest Share In The Multiple Myeloma Drugs Market?

North America was the largest region in the multiple myeloma drugs market in 2024. The regions covered in the multiple myeloma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11943&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model